Monotherapy for Dysthyroid Optic Neuropathy

Physician’s Weekly spoke recently with Roman Shinder, MD, FACS, from the Departments of Ophthalmology and Otolaryngology at SUNY Downstate Medical Center, about study results he and his colleague, Anna Artymowicz, MD, presented...

Read More

Teprotumumab for Long-Standing, Active TED

While phase II and III trials indicate that teprotumumab therapy can significantly reduce proptosis and Clinical Activity Score (CAS) in patients with recent-onset (< 8 months), untreated TED (except for steroid therapy >...

Read More

Recalcitrant TED Responsive to Teprotumumab

New research presented at the American Society of Ophthalmic Plastic & Reconstructive Surgery’s fall symposium highlighted the benefits of Tepezza (teprotumumab) for patients with thyroid eye and Graves disease....

Read More

For latest news and updates
Email-id is invalid